Bleeding Risks Low in 'Real World' Rivaroxaban Patients

ACC Conference Reporter

ESC 2015 | LONDON — A required post-marketing study indicates that the anticoagulant rivaroxaban (Xarelto) used for stroke prevention in patients with atrial fibrillation may have less bleeding safety issues than were seen in the drug's pivotal trial, researchers suggested here. Read More >>>

Keywords: ESC Congress

< Back to Listings